‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS)
Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...
Hims & Hers Zepbound Offering Won’t Bring Needed Sales Boom, Analysts Say
Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own ...
‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)
Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.
Modern Healthcare1d
Eli Lilly denies affiliation with Hims & Hers
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...
Explore more
Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty
Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of ...
What's Driving the Market Sentiment Around Hims & Hers Health?
Hims & Hers Health's HIMS short percent of float has risen 5.58% since its last report. The company recently reported that it has 54.73 million shares sold short, which is 28.0% of all regular shares ...